Labetalol Hcl Mylan (Labetalol Hydrochloride)

Labetalol Hydrochloride works by simultaneously blocking alpha‑1 adrenergic receptors, which relaxes blood vessels, and non‑selective beta‑adrenergic receptors, which reduces heart rate and cardiac output. This dual action decreases peripheral resistance and overall blood pressure.

The appropriate dose of Labetalol Hcl Mylan is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of Labetalol Hydrochloride in pregnancy and lactation has not been definitively established. Healthcare providers will weigh potential benefits against possible risks before prescribing it to pregnant or nursing individuals. Patients should discuss any concerns with their doctor.

To order Labetalol Hcl Mylan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Labetalol’s unique combination of alpha‑1 and non‑selective beta‑blockade differentiates it from agents that target only one receptor type. This dual mechanism can provide more balanced blood pressure reduction, especially in acute settings, whereas many other antihypertensives act solely on either the vascular tone or heart rate.

Labetalol Hcl Mylan should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Labetalol Hcl Mylan is taken orally, usually as a tablet. The exact dosing schedule, including the number of tablets and timing, is prescribed by a qualified healthcare professional and should be followed exactly as directed.

Serious risks include severe hypotension, bronchospasm in patients with reactive airway disease, hepatic dysfunction, and cardiac conduction abnormalities such as heart block or marked bradycardia. Patients should seek immediate medical attention if they experience symptoms like extreme dizziness, difficulty breathing, or fainting.

Labetalol is contraindicated in individuals with known hypersensitivity to labetalol or any component of the formulation, severe asthma or chronic obstructive pulmonary disease, and in patients with second‑ or third‑degree heart block without a pacemaker. Clinicians should evaluate each patient’s medical history before prescribing.